The Overlooked Majority: Why Cancer Care for Seniors Needs a Radical Rethink
Here’s a startling fact: in the Netherlands, half of all cancer patients are 70 or older. Yet, as PhD candidate Joosje Baltussen points out, this demographic is often treated as an afterthought in oncology. What’s even more striking is how little we know about how older adults respond to treatments. Personally, I think this gap in knowledge isn’t just a medical oversight—it’s a societal blind spot. As populations age globally, this issue isn’t confined to the Netherlands; it’s a ticking time bomb for healthcare systems worldwide.
The Myth of the ‘Older Patient’
One thing that immediately stands out is Baltussen’s assertion that there’s no such thing as a typical older patient. Some 75-year-olds are marathon runners, while others struggle with multiple chronic conditions. This diversity is captured in the term vulnerability, but it’s often misunderstood. Vulnerability isn’t just about age; it’s about physical, cognitive, and social functioning. What many people don’t realize is that treating older cancer patients without assessing this vulnerability is like navigating a maze blindfolded.
Baltussen advocates for a vulnerability assessment—a holistic evaluation that goes beyond age to consider a patient’s overall health and personal priorities. From my perspective, this approach is long overdue. It’s not just about medical outcomes; it’s about respecting the autonomy of older adults. For instance, some seniors might prioritize maintaining independence over extending life by a few months. This raises a deeper question: are we designing treatments for patients, or are we forcing patients to fit into treatment molds?
The Research Gap: A Silent Crisis
Here’s where the problem gets even more complicated: older adults are vastly underrepresented in clinical trials. Strict selection criteria often exclude them due to comorbidities or lower fitness levels. As a result, treatments are tested on younger, healthier populations and then extrapolated to older patients. If you take a step back and think about it, this is like testing a car on smooth roads and then expecting it to perform equally well off-road.
What this really suggests is that we’re making treatment decisions in the dark. Doctors are left to guess whether a treatment will be safe or effective for their older patients. A detail that I find especially interesting is how this uncertainty can lead to suboptimal care. For example, some seniors might abandon chemotherapy due to severe side effects, even though a lower dose might be tolerable. This isn’t just a medical issue—it’s a failure of the research ecosystem.
Side Effects and Shifting Priorities
Baltussen’s research reveals that vulnerable older patients are more likely to experience severe side effects from chemotherapy, such as infections or repeated hospitalizations. What makes this particularly fascinating is how these side effects disproportionately impact their quality of life. For younger patients, a few weeks of discomfort might be a small price to pay for survival. But for older adults, losing independence or the ability to live at home can be devastating.
In my opinion, this highlights a fundamental mismatch between treatment goals and patient priorities. Younger patients often focus on survival at all costs, while older adults frequently prioritize dignity and daily functioning. This isn’t just a medical decision—it’s a deeply personal one. Yet, our healthcare systems rarely account for this nuance.
Less Is More: The Case for Tailored Treatments
One of the most compelling insights from Baltussen’s work is that less-intensive treatments can yield better outcomes for older patients. Her ongoing research explores whether lower doses of chemotherapy for metastatic bowel cancer can reduce side effects without compromising effectiveness. Personally, I think this is a game-changer. It challenges the one-size-fits-all approach that dominates oncology.
What many people don’t realize is that this shift requires funding and support, which the pharmaceutical industry often doesn’t prioritize. Baltussen’s research was funded by organizations like the KWF Dutch Cancer Society, but such initiatives are the exception, not the rule. If you take a step back and think about it, this is a systemic issue. We’re leaving older patients behind because the financial incentives aren’t aligned with their needs.
The Way Forward: Personalized Care as a Human Right
The common thread in Baltussen’s work is the call for personalized care. As the number of vulnerable older cancer patients grows, we can’t afford to treat them as a homogeneous group. In my opinion, this isn’t just a medical imperative—it’s a moral one. Older adults deserve treatments that align with their unique circumstances and values.
What this really suggests is that we need a paradigm shift in oncology. It’s not enough to develop new drugs; we need to rethink how we test, prescribe, and evaluate treatments. From my perspective, this starts with including older adults in clinical trials and funding research that prioritizes their needs.
Final Thoughts
As I reflect on Baltussen’s work, I’m struck by how much we still have to learn. Treating older cancer patients isn’t just about extending life—it’s about enhancing it. Personally, I think this is one of the most pressing challenges in modern medicine. It’s not just about science; it’s about empathy, respect, and human dignity. If we get this right, we don’t just improve healthcare—we redefine what it means to age with grace and autonomy.
